Tobramycin cystic fibrosis foundation/pathogenesis

Current Opinion in Investigational Drugs

Volumn 2, Issue 6, 2001, Pages 755-765

  Singh, M P ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PA 1005; PLACEBO; PROTEIN SYNTHESIS INHIBITOR; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; BRONCHITIS; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SYNTHESIS; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG FUNCTION; LUNG INFECTION; MEDICAL NEBULIZER; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; POWDER INHALER; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TOBRAMYCIN;

EID: 0034784520     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (170)

1. PathoGenesis' product progress
2. PathoGenesis Corp - Prudential Securities Inc, Needham & Company Inc, Pacific Growth Equities Inc
3. PA-1005 (Tobramycin)
4. PathoGenesis' progress in cystic fibrosis and TB
5. Clinical trial update March 1996
6. PathoGenesis completes phase III trials in cystic fibrosis patients
7. Clinical Trials Update
8. Annual Report 1995 - PathoGenesis Corp
9. PathoGenesis has infectious diseases under control
10. Drug development pipeline
11. Cefepime/Tobramycin
12. Results - Journals
13. Results - Meetings
14. PathoGenesis Corp announces results of phase III trials in cystic fibrosis patients
15. Phase III results for PathoGenesis' CF drug
16. PathoGenesis Corp. Files for sale of 2 million shares in follow-on offering
17. PathoGenesis Corp announces FDA plans for expedited review of its lead drug candidate
18. PathoGenesis reports positive data for CF drug
19. Abbott Abbojet shrink-wrapped bundle packaging evaluation suggested by FDA
20. Product news in brief
21. Pseudomonas aeruginosa, tobramycin and minimum inhibitory concentration (MIC)
22. PathoGenesis Corp. Reports results for first quarter of 1997
23. PathoGenesis establishes European base
24. PathoGenesis files TOBI in US
25. PathoGenesis Corp announces European expansion
26. PathoGenesis Corp reports second quarter 1997 results
27. PathoGenesis initiates phase II clinical trial in bronchiectasis patients
28. PathoGenesis initiates phase II clinical trial in tuberculosis patients
29. PathoGenesis Corp reports third quarter 1997 results
30. FDA advisory committee unanimously recommends approval of TOBI for lung infections in people with cystic fibrosis
31. FDA panel backs CF product
32. PathoGenesis TOBI will be launched several days after approval
33. Analyst report 1997: Magainin
34. FDA grants marketing clearance for TOBI™ (tobramycin solution for inhalation)
35. 1997 good but not great for US biotech
36. First approval for PathoGenesis' TOBI
37. Analyst report - MedImmune and PathoGenesis: Exciting opportunities in late-stage respiratory drugs - October 1997
38. PathoGenesis Corp reports 1997 results, initial sales of its first drug
39. PathoGenesis Corp announces Canadian filing for approval of cystic fibrosis drug
40. PathoGenesis Corp receives NIH research grant to fund tuberculosis research
41. PathoGenesis files for Canadian approval of TOBI
42. PathoGenesis receives NIH grant to fund TB research
43. PathoGenesis to announce acquisition of TOBI license rights: Other news at annual meeting
44. Longer-term TOBI interim data to be presented at European cystic fibrosis meeting
45. PathoGenesis Corp completes patient enrollment for phase II trial in bronchiectasis patients
46. PathoGenesis Corp reports second quarter 1998 results; TOBI prescription sales increased more than 20% from first quarter
47. PathoGenesis Corp announces filing for regulatory approval of TOBI in Europe
48. PathoGenesis Corp third quarter 1998 results; TOBI sales increase 9% from second quarter
49. PathoGenesis Corp reports results of phase II trial of TOBI in bronchiectasis patients
50. Research published in the New England Journal of Medicine shows benefits of chronic aerosolized antibiotic therapy
51. PathoGenesis Canada Limited: American biotech company announces Canadian expansion
52. PathoGenesis Corp reports 1998 results, including its first annual profit
53. PathoGenesis Corp announces first international approvals of TOBI (Tobramycin solution for inhalation)
54. PathoGenesis Corp begins patient enrollment in TOBI clinical trial in the United Kingdom and Ireland
55. Strong clinical trial results in bronchietasis patients announced at ALA/ATS meeting
56. PathoGenesis Corp reports first quarter 1999 results
57. PathoGenesis launches its first drug in Canada
58. PathoGenesis Corp goes international
59. PathoGenesis Corp announces two-year data on TOBI
60. SG Cowen: Eli Lilly
61. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
62. PathoGenesis Corp reports second quarter 1999 results
63. Two-year data announced: TOBI helps patients live and breathe better, improves nutritional status without compromising safety
64. PathoGenesis Corp reports third quarter 1999 results, including a 16% sales increase from second quarter
65. Update on clinical trials in the treatment of pulmonary disease in patients with cystic fibrosis
66. PathoGenesis Corp gains UK approval of TOBI: First step toward approval in European Union
67. Ligand subsidiary sells royalty rights on Zenapax and Simulect to pharmaceutical partners
68. PathoGenesis Corp continues to expand internationally - Company announces drug approval in Israel
69. PathoGenesis to collaborate with Chiron on drug discovery and development
70. PathoGenesis Corp previews record fourth quarter 1999 sales, year 2000 growth plans at Hambrecht & Quist Conference - Sales exceed street consensus estimate
71. H&Q: Product pulse industry report
72. Amgen is biotech again; Genomic data drives sector to new heights
73. PathoGenesis Corp
74. PathoGenesis Corp reports strong fourth quarter 1999 sales results
75. Dinu Sen joins PathoGenesis Corp as a Senior Vice-President of Sales and Marketing
76. PathoGenesis TOBI use per patient can be raised about 50%, CEO says
77. PathoGenesis Corp announces further plans for expansion in Europe
78. Annual Report 1999 - PathoGenesis Corp
79. Quarterly report for the period ended September 30, 1999
80. Form 10-Q for the quarterly period ended June 30, 1999
81. Form 10-Q for the quarterly period ended March 21, 1999
82. Form 10-K for the fiscal year ended December 31, 1999
83. Australia approves PathoGenesis drug for marketing
84. PathoGenesis Corp announces distribution agreement in Italy
85. Collaboration agreement announced by PathoGenesis and AeroGen - Companies' goal: Speed up delivery of inhaled antibiotic for tough-to-treat lung infections
86. Annual Report 1999 - PathoGenesis Ltd
87. PathoGenesis Corp begins clinical trial of TOBI in cystic fibrosis patients with mild lung disease
88. PathoGenesis Corp receives European patent for inhaled antibiotic
89. UK clinical trial confirms benefits of TOBI lung function improved for TOBI patients, not for patients inhaling colistin
90. PathoGenesis Corp begins clinical trial of TOBI in patients with severe bronchiectasis study to lay groundwork for eventual phase III trial
91. PathoGenesis begins clinical trial of TOBI and AeroGen's handheld AeroDose inhaler: Goal is to improve convenience, reduce TOBI's delivery time
92. PathoGenesis Corp reports record revenues for second quarter 2000; company cites strong sales growth for TOBI in US and international markets
93. Chiron to acquire PathoGenesis: Acquisition expands Chiron's infectious disease franchises in biopharmaceuticals, vaccines and blood testing
94. Merrill Lynch: Global Healthcare Bulletin
95. Research published in American Journal of Respiratory and Critical Care Medicine shows benefits of inhaled antibiotic therapy. Clinical trial results demonstrate antimicrobial efficacy, improved medical condition in bronchiectasis patients
96. Chiron acquiring PathoGenesis for six times consensus 2001 revenues
97. PathoGenesis Corp begins clinical trial of TOBI in patients with ventilator-associated pneumonia
98. Chiron and PathoGenesis announce early termination of Hart-Scott-Rodino waiting period and completion of regulatory filings for PathoGenesis acquisition
99. Chiron reports 2000 third quarter results of 23 cents per share
100. Advances in Inhalation Therapy: IBC Conference National Heart & Lung Institute, London, UK
101. Delivery of Drugs by Inhalation: Henry Stewart Conference Studies London, UK
102. Axys Pharmaceuticals names Paul J Hastings President and Chief Executive Officer
103. TOBI approved in the European Union - Individual countries expected to issue marketing authorizations over next few months
104. A teratological study of aminoglycoside antibiotic treatment during pregnancy
105. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis
106. Disseminated gonococcal infection and meningitis
107. Reversible tobramycin-induced bilateral high-frequency vestibular toxicity
108. A comparative study of changes in fecal flora in patients preconditioned with either amphotericin B or fluconazole for allogeneic bone marrow transplantation
109. Biotechnology 'C'-saw year: Clialis boosts lcos, Coviracil costs Triangle
110. AeroGen Inc.
111. Chiron Corp.
112. Summary of the JP Morgan Hambrecht & Quist 19th Annual Healthcare Conference, San Francisco, CA, USA
113. Identification and characterization of inhibitors of multidrug resistant efflux pumps in P aeruginosa: Novel agents for combination therapy
114. Chiron reports solid 2000 results: Company reports 44% increase in 2000 pro-forma EPS Chiron Corp
115. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection
116. The role of the CFTR in susceptibility of Pseudomonas aeruginosa infections in cystic fibrosis
117. The place of tobramycin in lower respiratory tract infections (LRTI)
118. Tobramycin: A review of therapeutic uses and dosing schedules
119. The treatment of respiratory Pseudomonas infection in cystic fibrosis: What drug and which way?
120. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampicin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis
121. Endotoxin release from Escherichia coli after exposure to tobramycin: Dose-dependency and reduction in cefuroxime-induced endotoxin release
122. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection
123. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
124. Aminoglycoside antibiotics. Structure, function, and resistance
125. Nebramycin, a new broad-spectrum antibiotic complex I. Detection and biosynthesis
126. Nebramycin, a new broad-spectrum antibiotic complex II. Description of Streptomyces tenebrarius
127. Synthesis of 3′-deoxykanamycin B (tobramycin)
128. Synthesis of 5-deoxy-5-epifluoro derivatives of arbekacin, amikacin, and 1-N-[(S)-4-amino-2-hydroxybutanoyl]tobramycin (study on structure - Toxicity relationships)
129. A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: Teicoplanin plus tobramycin versus cephalothin plus tobramycin
130. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia
131. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of P aeruginosa
132. Administration of tobramycin aerosols in patients with nosocomial pneumonia: A preliminary study
133. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
134. Structures and biological activities of tobramycin-ticarcillin adducts
135. Laboratory findings of tobramycin and their relation to clinical response
136. Species-specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis
137. Influence of other antimicrobial agents on the microbiological assay of ethambutol
138. Aminoglycoside binding in the major groove of duplex RNA: The thermodynamic and electrostatic forces that govern recognition
139. Aminoglycoside resistance among nosocomial bacterial isolates
140. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment
141. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis
142. Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients
143. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis
144. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis
145. Lung distribution and pharmacokinetics of aerosolized tobramycin
146. Macromolecular mechanisms of sputum inhibition of tobramycin activity
147. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
148. Therapeutic drug monitoring of tobramycin: Once-daily versus twice-daily dosage schedules
149. Inhalation of tobramycin in cystic fibrosis Part 1: The choice of a nebulizer
150. Inhalation of tobramycin in cystic fibrosis Part 2: Optimization of the tobramycin solution for a jet and an ultrasonic nebulizer
151. Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation
152. Ototoxicity caused by aminoglycosides is ameliorated by melatonin without interfering with the antibiotic capacity of the drugs
153. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis
154. Tobramycin-induced hypersensitivity reaction
155. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis
156. Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria
157. Changes in strategies for optimal antibacterial therapy in cystic fibrosis
158. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth
159. Molecular biology, biochemistry and fermentation of aminoglycoside antibiotics
160. Tobramycin
161. Mutation breeding of high tobramycin-producing strain
162. Scale-up of tobramycin fermentation
163. Study on the fermentation characteristic of tobramycin by Streptomyces tenebrarius
164. Study on fermentation conditions of tobramycin
165. Distribution and elimination kinetics of intravenously and intramuscularly administered tobramycin in man
166. Quorum sensing inhibitors as broad-spectrum anti-infectives
167. Studies on the characters of a higher tobramycin producer